CRISPR Therapeutics CRSP Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's total debt?
- CRISPR Therapeutics (CRSP) reported total debt of $787.64M in Q1 2026.
- How has CRISPR Therapeutics's total debt changed year-over-year?
- CRISPR Therapeutics's total debt increased by 259.1% year-over-year, from $219.36M to $787.64M.
- What is the long-term trend for CRISPR Therapeutics's total debt?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total debt has grown at a 27.5% compound annual growth rate (CAGR), from $61.43M to $206.75M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.